Dashboard
AstraZeneca PLC
AZNNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16RegulatorySEC
AstraZeneca's Klygefa (gefurulimab) approved in the EU.
- Nov 16RegulatorySEC
AstraZeneca's Imfinzi + EV approved in US for bladder cancer
- Nov 16RegulatorySEC
AstraZeneca's Klygefa (gefurulimab) approved in the US
- Nov 16RegulatorySEC
6-K: Baxfendy recommended for approval in the EU
- Nov 10Ownership changeSEC
SEC Form 4 insider transaction filing.
- Nov 2Securities offeringSEC
AstraZeneca 6-K reports admission of further securities to trading.
- Nov 2OtherSEC
AstraZeneca 6-K discloses total voting rights.
- Oct 30Financial resultsSEC
AstraZeneca PLC files 6-K disclosing third quarter results.
- Oct 27RegulatorySEC
ENHERTU approved in EU for HER2-positive early breast cancer (EBC).
- Oct 22RegulatorySEC
Ultomiris approved in the US for IgA nephropathy per 6-K filing.
- Oct 8Ownership changeSEC
SEC Form 4 insider transaction filing reported for AZN.
- Oct 5DealSEC
AstraZeneca completes equity investment in Summit per 6-K filing.
- Oct 2PartnershipSEC
AstraZeneca and Daiichi Sankyo collaboration with Summit for Datroway.
- Oct 1Securities offeringSEC
AstraZeneca 6-K reports admission of further securities to trading.
- Oct 1OtherSEC
AstraZeneca 6-K discloses total voting rights as of filing date.
- Sep 29DealSEC
AstraZeneca announces equity investment in Summit via 6-K filing.
- Sep 23RegulatorySEC
Trixeo approved in EU for asthma per 6-K filing.
- Sep 21RegulatorySEC
Klygefa recommended for EU approval by CHMP
- Sep 21RegulatorySEC
ENHERTU recommended for approval in EU for early breast cancer
- Sep 18Ownership changeSEC
6-K reports director/PDMR shareholding notification for AstraZeneca.
Not financial advice — research and opinion only. Disclosures